This interactive map illustrates the overlap in HIV prevalence in women and the total addressable market for contraception (women currently using a modern method as well as those who plan to use contraception in the future) to illustrate the hot spots where an MPT that combines HIV prevention and contraception might have the greatest impact. This map focuses on Sub-Saharan African women aged 15 to 24, and was updated in May 2019 to include the contraceptive method mix.

View Mapping Tool
Download Project Summary Report
Watch Video Walk-Through
Download How to Use the MPT Target Population Identification Mapping Tool

In this second webinar in the IMPT’s “Let’s Talk MPTs” series, we discuss that integrating end-user perspectives into the development of MPT development is critical to ensure such products are used and are successful. We bring together MPT developers with product candidates in different stages of development, and socio-behavioral and clinical researchers for an engaging dialogue about the socio-behavioral and market research needs of the MPT field. This second webinar in the “Let’s Talk MPTs” series builds upon the NICHD socio-behavioral research workshop from September 2020 and a USAID funded Biomedical HIV Prevention Product Investment Framework.

View Webinar Recording
Download Presentation
Download Suggested Readings
Read the Report on Roadmap for Biomedical HIV Prevention Investment Standards

This brief features findings from the Tablets, Ring, Injections as Options (TRIO) study, with a focus on long-acting injections as a delivery form for HIV prevention for women and a potential delivery form for MPTs. 

With injections as a new biomedical HIV prevention strategy on the horizon, the TRIO study’s end-user findings from women and healthcare providers, as outlined in this brief, provide a timely contribution to late-stage product development. Further, they inform market introduction considerations for rollout of injectable delivery forms for women.

TRIO was a multiphase study conducted with young women in Kenya and South Africa between 2015 and 2017 to understand their perspectives on future MPTs. It was led by RTI International with support from the Bill & Melinda Gates Foundation.

View Brief

This report by Dr. Betsy Tolley (FHI 360) presents learnings and reflections on traditional socio-behavioral research (SBR) and human-centered design (HCD) as applied to the global health context – specifically in biomedical prevention for sexual and reproductive health. In comparing these methodologies and examining their strengths and shortcomings, we can identify potential synergies to further inform the development and eventual introduction of MPTs in targeted end-user populations. Also, check out Elizabeth Russell’s companion piece on the USAID Office of HIV/AIDS Research Blog.

Click here to view report

Click here to view companion piece

The United States Agency for International Development (USAID) is a major funder of biomedical HIV prevention product development. In response to USAID’s desire for standards to help guide decisions for prioritizing investments and integrating user perspectives at various stages of product development, the Initiative for MPTs (IMPT) provided technical assistance to USAID’s Office of HIV/AIDS (OHA) to develop a Biomedical HIV Prevention Product Investment Framework. The purpose of this framework is to provide high-level guidance for USAID on biomedical HIV prevention investment decisions that integrate user perspectives at various stages of product development, namely from the pre-clinical/discovery to regulatory phases. Critical to the development of this framework were consultations with experts representing global pharmaceutical organizations, smaller biotechnology companies, non-profit product developers, academia, and supporting agencies. 

Read the report